Phase I study of MVE-2 evaluating toxicity and biologic response modification capability

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• MVE-2, a pyran copolymer component, is a biological response modifier.
• Phase I trials evaluate drug safety and dosage.
• Biological response modifiers aim to enhance the host's immune response against cancer.

Purpose of the Study:

• To assess the safety and tolerability of MVE-2 in cancer patients.
• To determine the dose-limiting toxicity of MVE-2.
• To evaluate the immunomodulatory effects of MVE-2.

Main Methods:

• A phase I clinical trial involving 21 patients treated with MVE-2 intravenously over 2 hours weekly.
• Dose escalation to identify the maximum tolerated dose.
• Monitoring for toxicities, particularly proteinuria.
• Assays to measure changes in immune cell activity, including natural cell-mediated cytotoxicity.

Main Results:

• Proteinuria, sometimes nephrotic, was the dose-limiting toxicity, occurring above 2500 mg cumulative dose.
• Minimal other toxicities were observed.
• Biologic response modification was inconsistent at tolerable doses.
• Enhanced immune activity, particularly cytotoxicity, was noted at higher MVE-2 doses.
• No objective tumor responses were observed.
• Subsequent administration via 30-min infusion in 8 patients showed no proteinuria despite large cumulative doses.

Conclusions:

• MVE-2's initial administration method was limited by dose-limiting proteinuria before achieving consistent immunomodulation.
• Alternate MVE-2 administration schedules, such as shorter infusions, may mitigate proteinuria.
• Further investigation into optimized MVE-2 dosing and schedules is warranted to explore its potential as an immunomodulator.